Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Coagulopathy of Immunodermatologic Diseases

University of Nebraska · NCT06037187

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 19+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
39
US sites recruiting
1
Study start
May 9, 2023
Record last updated
May 12, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will examine the coagulation and fibrinolysis profiles of those with autoimmune skin diseases. Blood samples will be collected from participants with active/poorly controlled immune-mediated skin diseases and mild/latent/well-controlled immune-mediated skin diseases. A one-time sample from 15 general dermatology outpatients who do not have a known or suspected diagnosis of bullous diseases, immune-mediated dermatologic condition, or cutaneous malignancy will also be collected to serve as control. Blood samples from both participant populations will be analyzed for coagulation and inflammatory markers and compared. The results of this study may help inform future studies on the utility of analyzing coagulation and fibrinolysis profiles of patients with autoimmune skin diseases.

Being studied: Blood Draw

Conditions: Autoimmune Bullous Dermatosis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis
  • For control group: no diagnosis of immune-mediated skin
  • For study group: receiving care from one or more of the Principal or Secondary Investigators

Exclusion Criteria

  • Unfit to provide consent
  • P2Y12 inhibitor use in the past 4 weeks
  • History of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies)
  • Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study
  • Other autoimmune diseases not in remission defined as flare in the last 12 weeks
  • If patient is unable to provide detailed history and if we do not have sufficient history on record.
  • Less than 19 years of age

Recruiting US locations

  • University of Nebraska Medical Center

    Omaha, NE 68198

    Site contact: Megan E Wackel, MS · 402-559-3825 · megan.wackel@unmc.edu

Study contacts (from the official record)

  • Megan E Wackel, MS · 402-559-3825 · megan.wackel@unmc.edu
All healthy volunteers studies in Nebraska →
Coagulopathy of Immunodermatologic Diseases (NCT06037187) | Bored Studies